Since the discovery of ROCK1 inhibitors, accumulating evidence supports that ROCK1 could be a potential therapeutic target for cancers, including breast cancer, colon cancer and hepatocellular carcinoma [14,15,16,17]. The gene discussed is ROCK1; the disease is hepatocellular carcinoma.